ECU
UTHR icon

Eisler Capital (UK)’s United Therapeutics UTHR Stock Holding History

Eisler Capital (UK)’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-3,640
Closed -$836K – 662
2024
Q1 		$836K Sell
3,640
-3,155
-46% -$712K 0.01% 529
2023
Q4 		$1.49M Buy
+6,795
New +$1.57M 0.01% 441

Other funds holding UTHR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Eisler Capital (UK)'s UTHR Position: Q2 2024 in Review

Eisler Capital (UK) sold out of United Therapeutics (UTHR) in Q2 2024, closing a stake of 3,640 shares — an estimated $836K sold.

Eisler Capital (UK) first reported a position in UTHR in Q4 2023 and held it in 2 quarters. The position peaked at $1.49M in Q4 2023. 566 funds tracked by Wall St. Rank hold UTHR as of Q2 2024.

  • Eisler Capital (UK) reported no remaining United Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Eisler Capital (UK) sold 3,640 United Therapeutics shares in Q2 2024, an estimated $836K.
  • Eisler Capital (UK) first reported a position in United Therapeutics in Q4 2023 and held it in 2 quarters.
  • Eisler Capital (UK)'s United Therapeutics position peaked at $1.49M in Q4 2023.
  • 566 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2024.

Based on Eisler Capital (UK)'s 13F filing for Q2 2024, filed 13 Aug 2024.